Mylan Pharma UK Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 1961-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.mylan.co.uk
Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution
Phase 1
Completed
- Conditions
- Healthy Volunteers Bioavailability Study
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05207111
- Locations
- 🇨🇳
Xuzhou Central Hospital, Xuzhou, China
Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Phase 3
Completed
- Conditions
- COPD
- Interventions
- Drug: Placebo inhalation solution QD
- First Posted Date
- 2021-09-16
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT05046795
- Locations
- 🇨🇳
Wuxi People's Hospital, Wuxi, Jiangsu, China
🇨🇳Yangzhou First People's Hospital, Yangzhou, Jiangsu, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
An Open Study to Assess the Robustness of the CRC749 Inhaler
- First Posted Date
- 2015-06-17
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT02474017
- Locations
- 🇬🇧
Mylan Investigational Site, Manchester, United Kingdom
MGR001 / Advair Diskus Local Equivalence Study in Asthma
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 1128
- Registration Number
- NCT02245672
- Locations
- 🇺🇸
Mylan Investigative Site #14, Los Angeles, California, United States
🇺🇸Mylan Investigative Site #42, Bangor, Maine, United States
🇺🇸Mylan Investigative Site #74, Medford, Oregon, United States
Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs
Phase 1
Completed
- Conditions
- AsthmaCOPD
- Interventions
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- Mylan Pharma UK Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02215122
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath